Zydus Lifesciences Ltd.
ZYDUSLIFE
979.6
0.00 (0.68%)The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses.
Shareholding Pattern
| On | Ind. Pro. | Fore. Pro. | FII/FPI | Mutual Funds | Banks | Insurance | Others | Non/Institution |
|---|---|---|---|---|---|---|---|---|
| 2024-09 | 74.98 | 0 | 7.52 | 6.57 | 0 | 3.85 | 0.23 | 6.85 |
| 2024-06 | 74.98 | 0 | 5.59 | 7.24 | 0 | 5.22 | 0.17 | 6.79 |
| 2024-03 | 74.98 | 0 | 5.72 | 6.71 | 0 | 5.74 | 0.18 | 6.66 |
| 2023-12 | 74.98 | 0 | 4.99 | 6.99 | 0.02 | 5.8 | 0.23 | 6.99 |
| 2023-09 | 74.98 | 0 | 4.85 | 5.94 | 0 | 6.86 | 0.30 | 7.07 |
| 2023-06 | 74.98 | 0 | 4.04 | 5.8 | 0 | 7.43 | 0.29 | 7.47 |
| 2023-03 | 74.98 | 0 | 3.42 | 5.59 | 0 | 7.67 | 0.34 | 8 |
| 2022-12 | 74.98 | 0 | 2.51 | 5.56 | 0 | 7.87 | 0.27 | 8.81 |
| 2022-09 | 74.98 | 0 | 2.6 | 5.36 | 0.01 | 7.3 | 0.26 | 9.49 |
Results
| On | Income from Inv. | Int. on Bank Bal. | Int. on Advances | Other Int. | Interest Earned | Interest Exp. | Net Interest Income | Expenditure | Operating Income | Other Income | Prov. & Contingencies | PBT | Tax | PAT | Net Profit | Consolidated Net Profit | Adjusted EPS(Rs.) | Gross NPA | Gross NPA(%) | Net NPA | Net NPA(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09 | 0 | 0 | 0 | 0 | 5237 | 25.1 | 5211.9 | 3821 | 1529.6 | 113.6 | 0 | 1270.9 | 373.1 | 897.8 | 898.1 | 911.2 | 9.06 | 0 | 0% | 0 | 0% |
| 2024-06 | 0 | 0 | 0 | 0 | 6207.5 | 32.2 | 6175.3 | 4123.5 | 2147.2 | 63.2 | 0 | 1899.7 | 436.1 | 1463.6 | 1463.6 | 1419.9 | 14.11 | 0 | 0% | 0 | 0% |
| 2024-03 | 0 | 0 | 0 | 0 | 5533.8 | 34.6 | 5499.2 | 3908.6 | 1786.9 | 161.7 | 0 | 1547 | 321.2 | 1225.8 | 1229 | 1182.3 | 11.75 | 0 | 0% | 0 | 0% |
| 2023-12 | 0 | 0 | 0 | 0 | 4505.2 | 19.8 | 4485.4 | 3423.4 | 1140.1 | 58.3 | 0 | 925.5 | 213.8 | 711.7 | 733.5 | 789.6 | 7.80 | 0 | 0% | 0 | 0% |
| 2023-09 | 0 | 0 | 0 | 0 | 4368.8 | 8.7 | 4360.1 | 3304.9 | 1200.1 | 136.2 | 0 | 1007.2 | 226.4 | 780.8 | 779.8 | 800.7 | 7.91 | 0 | 0% | 0 | 0% |
| 2023-06 | 0 | 0 | 0 | 0 | 5139.6 | 18.1 | 5121.5 | 3634.3 | 1541.3 | 36 | 0 | 1329.2 | 216.1 | 1113.1 | 1112.1 | 1086.9 | 10.74 | 0 | 0% | 0 | 0% |
| 2023-03 | 0 | 0 | 0 | 0 | 5010.6 | 27.7 | 4982.9 | 3755 | 1293.4 | 37.8 | 0 | 485.8 | 137.2 | 348.6 | 346.4 | 296.6 | 2.93 | 0 | 0% | 0 | 0% |
| 2022-12 | 0 | 0 | 0 | 0 | 4257.1 | 32.8 | 4224.3 | 3406.3 | 994.5 | 143.7 | 0 | 780.1 | 195.2 | 584.9 | 585.3 | 622.9 | 6.16 | 0 | 0% | 0 | 0% |
| 2022-09 | 0 | 0 | 0 | 0 | 4005.5 | 35.1 | 3970.4 | 3319.4 | 859.7 | 173.6 | 0 | 642.8 | 137 | 505.8 | 511.3 | 522.5 | 5.16 | 0 | 0% | 0 | 0% |
| 2022-06 | 0 | 0 | 0 | 0 | 3964.3 | 34.3 | 3930 | 3239.7 | 898.9 | 174.3 | 0 | 681 | 118.4 | 562.6 | 554.3 | 518.3 | 5.06 | 0 | 0% | 0 | 0% |